Pharmaceutical News and Articles

16 Updates, Four New Recommendations Issued for Management of Pediatric VTE

In clinical guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Haemostasis, and published online May 27 in

Substantial and Increasing Burden of Skin Cancer Seen in Older Adults

Older adults have a substantial and increasing burden of skin cancer, according to a study published online May 21 in JAMA Dermatology.Ruiyao Wang, M.D., from T

Longer In-Bed Time Linked to Small Vessel Disease Burden in TIA/Mild Stroke

For adult patients with transient ischemic attack (TIA) mild stroke, disturbed sleep is associated with greater cerebral small vessel disease (SVD) burden and w

FDA Chief: COVID Vaccine in Pregnancy Should Be Personal Choice

FRIDAY, May 30, 2025 Federal health officials have pulled back a key recommendation that pregnant women get the COVID-19 vaccine causing sharp criticism from do

Teva Celiac Disease Candidate TEV-53408 Granted Fast Track Designation by US FDA

Teva Pharmaceutical Industries, Ltd. (NYSE and TASE TEVA) today announced that the US Food and Drug Administration (FDA) granted Fast Track designation for inve

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Rocket Pharmaceuticals, Inc. (NASDAQ RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST - Modifier Gene Therapy for the Treatment of Stargardt Disease

Ocugen, Inc. (Ocugen or the Company) (NASDAQ OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Singapore, 28 May 2025 The Experimental Drug Development Centre (EDDC), Singapore s national platform for drug discovery and development, today announced that t

NIH Scientists Pioneer Promising Treatment for Intractable Cancer Pain

National Institute of Health (NIH) scientists report that a first-in-human clinical trial of a new therapy based on the plant-derived molecule resiniferatoxin (

Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)